Evidence map›Paper›PMID 42376934›Full record

ArticleMuscle & nerve2026

Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study.

Meg Mendoza, Elena Wolff, Michael Chou, Vera Bril, Hans Katzberg, Ahmed Bayoumi, Carolina Barnett-Tapia

Abstract read
In one paragraph

Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meg MendozaEllen and Martin Prosserman Centre for Neuromuscular Disease, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-6458-3618
Elena WolffEllen and Martin Prosserman Centre for Neuromuscular Disease, Toronto, Ontario, Canada.
Michael ChouEllen and Martin Prosserman Centre for Neuromuscular Disease, Toronto, Ontario, Canada.
Vera BrilEllen and Martin Prosserman Centre for Neuromuscular Disease, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-5805-4883
Hans KatzbergEllen and Martin Prosserman Centre for Neuromuscular Disease, Toronto, Ontario, Canada.
Ahmed BayoumiMAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
Carolina Barnett-TapiaEllen and Martin Prosserman Centre for Neuromuscular Disease, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0001-5546-0221

Funding

MG Net. Myasthenia Gravis Rare DIsease NetworkMuscular Dystrophy Canada
6 · The paper itself

Abstract

INTRODUCTION/

aimsThe burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment-related adverse events also contribute to patients' burdens and affect their treatment decisions. Understanding the treatment preferences of people with MG will help inform patients, clinicians, and policy makers. We conducted a qualitative study to understand the most relevant factors that people with MG consider when making treatment decisions.

methodsFifteen patients with a wide range of MG severity participated in semi-structured interviews. Interviews were recorded and transcripts were analyzed using line-by-line open coding to generate themes. We used these themes to identify the most relevant treatment characteristics for people living with MG.

resultsFour themes were identified: MG symptoms, treatment side effects, treatment delivery preferences, and treatment goals. Double vision was the most bothersome symptom for 40% of patients, and 33% reported weight gain as the most bothersome side effect of treatment. Most patients preferred treatments in the form of pills (67%). The most frequently reported treatment goals were returning to normal or "zero symptoms" (40%), discontinuation of prednisone (40%), and a preference to take fewer pills (33%). DISCUSSION: Our results underscore the importance of tailoring treatments to meet patient needs and preferences, emphasizing key treatment goals such as prednisone reduction, a preference for oral medications, and symptom resolution. We will incorporate these themes into a discrete choice experiment to gain a deeper understanding of how people with MG make treatment decisions when considering potential benefits and adverse events.

Indexed as

Myasthenia GravisPatient PreferenceAdultAgedFemaleHumansMaleMiddle AgedPrednisoneQualitative ResearchPrednisoneadverse eventsmyasthenia gravisqualitative studytreatment goalstreatment preferences

Identifiers

PMID42376934
PMCPMC13599467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.